<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024647</url>
  </required_header>
  <id_info>
    <org_study_id>CMZ-2010</org_study_id>
    <nct_id>NCT01024647</nct_id>
  </id_info>
  <brief_title>Optimizing Cimzia in Crohn's Patients</brief_title>
  <official_title>Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atlanta Gastroenterology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atlanta Gastroenterology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if increasing the dose and/or dosing frequency of
      certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients
      with moderate to severe Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label study for patients with moderate to severe Crohn's disease will evaluate
      treatment options to improve capture of initial response and to regain loss of response to
      certolizumab pegol (Cimzia). It is a 26 week open label clinical trial that may be extended
      to 52 weeks in patients who respond to treatment during the initial 26 week study. The
      following dosing options will be tested: 1) Re-induction (one supplemental dose of 400mg) 2)
      Dose splitting (200mgQ2W) and 3) Dose Escalation (400mg Q2W. The highest dose in the study,
      400mg Q2W, has been used in a large phase III trial (WELCOME) without any new safety signals.
      Efficacy and safety measures will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crohn's Disease Activity Index</measure>
    <time_frame>26 Weeks, if responder up to 52 weeks</time_frame>
    <description>â‰¥ 100 point decrease in CDAI represents response</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Loss of Reponse Reinduction Responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Response loss Reinduction Non-Responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>certolizumab pegol</intervention_name>
    <description>certolizumab pegol 200 mg every 2 weeks</description>
    <arm_group_label>Loss of Reponse Reinduction Responders</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>certolizumab pegol</intervention_name>
    <description>certolizumab pegol 400 mg every 2 weeks</description>
    <arm_group_label>Response loss Reinduction Non-Responders</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>certolizumab pegol</intervention_name>
    <description>certolizumab pegol 400 mg every 4 weeks</description>
    <arm_group_label>Responders</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>certolizumab pegol</intervention_name>
    <description>certolizumab pegol 400 mg every 2 weeks</description>
    <arm_group_label>Non-Responders</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ileal and/or colonic Crohn's disease

          -  moderate to severe Crohn's disease

        Exclusion Criteria:

          -  short bowel syndrome

          -  ostomy

          -  anti-TNF therapy within 4 weeks

          -  prior certolizumab therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas C Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Gastroenterology Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lamia S Mereby, BSN</last_name>
    <phone>404-257-9000</phone>
    <phone_ext>2142</phone_ext>
    <email>lamia.mereby@atlantagastro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashleigh K Arnold, BS</last_name>
    <phone>404-257-9000</phone>
    <phone_ext>2138</phone_ext>
    <email>ashleigh.kapperman@atlantagastro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lamia S Mereby, BSN</last_name>
      <phone>404-257-9000</phone>
      <phone_ext>2142</phone_ext>
      <email>lamia.mereby@atlantagastro.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atlanta Gastroenterology Associates</investigator_affiliation>
    <investigator_full_name>Douglas C. Wolf, MD</investigator_full_name>
    <investigator_title>Medical Director of Clinical Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

